FAQ on Calidi Biotherapeutics Inc.'s CLD-401 Data Unveiled at ASCO 2025
Summary
What is CLD-401 and what does it do?
CLD-401 is Calidi Biotherapeutics’ lead therapeutic candidate from the RedTail platform, designed as an enveloped oncolytic virus with a novel genetic modification incorporating a chimeric CD55 receptor to enhance resistance to immune clearance for systemic delivery in treating cancer.
Why is the data on CLD-401 significant?
The data demonstrates a breakthrough in systemic oncolytic targeted immunotherapies by showing enhanced resistance to rapid clearance by the humoral immune system, potentially improving the efficacy of cancer treatments targeting metastatic sites.
How does CLD-401’s technology work?
CLD-401’s technology involves an engineered enveloped oncolytic virus that incorporates a chimeric CD55 receptor into its envelope, acting as a robust inhibitor of complement to shield the virus from immune clearance, allowing it to reach and target tumor sites more effectively.
Who is developing CLD-401?
CLD-401 is being developed by Calidi Biotherapeutics Inc., a clinical-stage biotechnology company specializing in systemic oncolytic targeted immunotherapies.
Where was the data on CLD-401 presented?
The promising new data on CLD-401 was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2025.
What types of cancer is CLD-401 targeting?
CLD-401 is currently in IND-enabling studies targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need.
How can I learn more about Calidi Biotherapeutics and CLD-401?
For more information, visit Calidi Biotherapeutics’ website at www.CalidiBio.com or check the latest news and updates relating to CLDI at https://ibn.fm/CLDI.
What is the RedTail platform?
The RedTail platform is Calidi Biotherapeutics’ proprietary technology featuring engineered enveloped oncolytic viruses designed for systemic delivery and targeting of metastatic sites, with the aim of shielding the virus from immune clearance to enhance treatment efficacy.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 110069